The tumorigenic effect of Bcl-2 was first described in subsets of non-Hodgkin’s lymphoma (NHL), such as AML, where it has been found to be associated with chemoresistance and unfavorable outcomes [14,15,16]. This evidence concerns the gene BCL2 and non-Hodgkin lymphoma.